We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Launch of Foot and Ankle Trauma Solutions May Boost ZBH Stock
Read MoreHide Full Article
Key Takeaways
ZBH expands its foot & ankle trauma portfolio with Gorilla Pilon Fusion and Phantom TTC launches.
ZBH reinforces commitment to surgical innovation, targeting complex pilon fractures and hindfoot injuries.
ZBH shares dipped post-announcement, but the launches may drive renewed momentum in stock performance.
Zimmer Biomet Holdings (ZBH - Free Report) , together with its subsidiary Paragon 28, has announced the full commercial launch of two solutions for complex foot and ankle trauma. The Gorilla Pilon Fusion Plating System and the Phantom TTC Trauma Nail are designed to offer advanced options to surgeons to address challenging pilon fractures and hindfoot injuries with precision and efficiency.
The latest development significantly expands the company’s foot and ankle trauma portfolio.
ZBH Stock’s Likely Trend Following the News
Following the Oct. 8 announcement, Zimmer Biomet shares slipped 0.7%, closing at $98.36 on Wednesday. On a promising note, the introduction of these two products underscores the company’s ongoing commitment to advancing innovations that help surgeons safely and efficiently tackle complex clinical problems. We expect the news to help support a rebound in ZBH stock’s performance.
Zimmer Biomet has a market capitalization of $19.48 billion. The company’s earnings yield of 8.3% compares favorably with the industry average of 0.1% yield. In the trailing four quarters, it delivered an average earnings surprise of 1.8%.
Significance of ZBH’s New Launch
The Gorilla Pilon Fusion Plating System provides a solution for primary tibiotalar fusion in patients with pilon fractures. These account for roughly 7% to 10% of all tibial fractures, with a small but clinically significant group of patients requiring primary ankle fusion due to severe comminution or articular surface loss.
Developed in collaboration with leading orthopedic trauma foot and ankle surgeons, the system offers stable dual-column fixation for severe or malunited tibial pilon fractures. Its anatomically contoured plates, precision-engineered instrumentation, and streamlined workflow enable stable fixation and fusion in a single procedure.
Image Source: Zacks Investment Research
Dual-plating constructs — available in various lengths — feature contoured anterolateral and medial options, optimized for both open and percutaneous approaches. Type II anodized plates are biomechanically engineered with region-specific thickness and tapered ends to reduce soft tissue disruption. The System also includes advanced percutaneous guides, long-shaft plate designs to span metaphyseal comminution and comprehensive joint preparation instrumentation.
Meanwhile, the Phantom TTC Trauma Nail builds on the proven Phantom TTC Nail platform. It provides expanded lengths and fixation capabilities to manage more demanding trauma cases, including complex pilon fractures requiring tibiotalocalcaneal fusion.
The solution incorporates the PRECISION Guide Technology for consistent, accurate nail placement and an integrated internal compression mechanism that delivers up to 8 mm of controlled compression. Other key features include advanced threaded peg options with multiple targeting configurations, as well as right and left-specific configurations and diameters for tailored fixation.
Industry Prospects Favor ZBH Stock
Per a report from Grand View Research, the global foot and ankle device market was valued at $4.76 billion in 2024 and is expected to witness a compound annual growth rate of 7.1% through 2030.
The increasing adoption of minimally invasive treatments is a key driver of growth in the market, given their advantages over traditional open surgeries. The growing prevalence of target diseases, such as osteoporosis, also fuels the market’s growth.
Other Developments at ZBH
Zimmer Biomet recently completed the acquisition of Monogram Technologies, an AI-driven, next-generation orthopedic robotics company. The acquisition expands the company’s extensive suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively.
ZBH Stock Price Performance
In the past three months, ZBH shares have rallied 3.8% compared with the industry’s 0.2% growth.
ZBH’s Zacks Rank & Key Picks
Zimmer Biomet currently carries a Zacks Rank #3 (Hold).
Estimates for Phibro Animal Health’s fiscal 2026 earnings per share have increased 3.3% to $2.53 in the past 30 days. Shares of the company have surged 58.5% in the past year compared with the industry’s 0.2% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%. In the last reported quarter, it delivered an earnings surprise of 9.6%.
Masimo shares have jumped 7% in the past year. Estimates for the company’s 2025 earnings per share have remained constant at $5.30 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Cardinal Health’s fiscal 2026 earnings per share have increased 1 cent to $9.42 in the past 30 days. Shares of the company have rallied 39.7% over the past year compared with the industry’s 3.6% growth. CAH’s earnings topped estimates in each of the trailing four quarters, the average surprise being 9.2%. In the last reported quarter, it posted an earnings surprise of 2.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Launch of Foot and Ankle Trauma Solutions May Boost ZBH Stock
Key Takeaways
Zimmer Biomet Holdings (ZBH - Free Report) , together with its subsidiary Paragon 28, has announced the full commercial launch of two solutions for complex foot and ankle trauma. The Gorilla Pilon Fusion Plating System and the Phantom TTC Trauma Nail are designed to offer advanced options to surgeons to address challenging pilon fractures and hindfoot injuries with precision and efficiency.
The latest development significantly expands the company’s foot and ankle trauma portfolio.
ZBH Stock’s Likely Trend Following the News
Following the Oct. 8 announcement, Zimmer Biomet shares slipped 0.7%, closing at $98.36 on Wednesday. On a promising note, the introduction of these two products underscores the company’s ongoing commitment to advancing innovations that help surgeons safely and efficiently tackle complex clinical problems. We expect the news to help support a rebound in ZBH stock’s performance.
Zimmer Biomet has a market capitalization of $19.48 billion. The company’s earnings yield of 8.3% compares favorably with the industry average of 0.1% yield. In the trailing four quarters, it delivered an average earnings surprise of 1.8%.
Significance of ZBH’s New Launch
The Gorilla Pilon Fusion Plating System provides a solution for primary tibiotalar fusion in patients with pilon fractures. These account for roughly 7% to 10% of all tibial fractures, with a small but clinically significant group of patients requiring primary ankle fusion due to severe comminution or articular surface loss.
Developed in collaboration with leading orthopedic trauma foot and ankle surgeons, the system offers stable dual-column fixation for severe or malunited tibial pilon fractures. Its anatomically contoured plates, precision-engineered instrumentation, and streamlined workflow enable stable fixation and fusion in a single procedure.
Image Source: Zacks Investment Research
Dual-plating constructs — available in various lengths — feature contoured anterolateral and medial options, optimized for both open and percutaneous approaches. Type II anodized plates are biomechanically engineered with region-specific thickness and tapered ends to reduce soft tissue disruption. The System also includes advanced percutaneous guides, long-shaft plate designs to span metaphyseal comminution and comprehensive joint preparation instrumentation.
Meanwhile, the Phantom TTC Trauma Nail builds on the proven Phantom TTC Nail platform. It provides expanded lengths and fixation capabilities to manage more demanding trauma cases, including complex pilon fractures requiring tibiotalocalcaneal fusion.
The solution incorporates the PRECISION Guide Technology for consistent, accurate nail placement and an integrated internal compression mechanism that delivers up to 8 mm of controlled compression. Other key features include advanced threaded peg options with multiple targeting configurations, as well as right and left-specific configurations and diameters for tailored fixation.
Industry Prospects Favor ZBH Stock
Per a report from Grand View Research, the global foot and ankle device market was valued at $4.76 billion in 2024 and is expected to witness a compound annual growth rate of 7.1% through 2030.
The increasing adoption of minimally invasive treatments is a key driver of growth in the market, given their advantages over traditional open surgeries. The growing prevalence of target diseases, such as osteoporosis, also fuels the market’s growth.
Other Developments at ZBH
Zimmer Biomet recently completed the acquisition of Monogram Technologies, an AI-driven, next-generation orthopedic robotics company. The acquisition expands the company’s extensive suite of orthopedic robotics, enabling solutions and analytics to address the needs of surgeons pre-, intra- and post-operatively.
ZBH Stock Price Performance
In the past three months, ZBH shares have rallied 3.8% compared with the industry’s 0.2% growth.
ZBH’s Zacks Rank & Key Picks
Zimmer Biomet currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space include Phibro Animal Health (PAHC - Free Report) , Masimo (MASI - Free Report) and Cardinal Health (CAH - Free Report) . While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy), Masimo and Cardinal Health each carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Phibro Animal Health’s fiscal 2026 earnings per share have increased 3.3% to $2.53 in the past 30 days. Shares of the company have surged 58.5% in the past year compared with the industry’s 0.2% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%. In the last reported quarter, it delivered an earnings surprise of 9.6%.
Masimo shares have jumped 7% in the past year. Estimates for the company’s 2025 earnings per share have remained constant at $5.30 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Cardinal Health’s fiscal 2026 earnings per share have increased 1 cent to $9.42 in the past 30 days. Shares of the company have rallied 39.7% over the past year compared with the industry’s 3.6% growth. CAH’s earnings topped estimates in each of the trailing four quarters, the average surprise being 9.2%. In the last reported quarter, it posted an earnings surprise of 2.5%.